Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients

Şahin O., Akan E., Tatar B., Ekmekcioğlu C., Ünal N., Odabaşı O.

Prospective Study with a reported sample of 3 on Chronic Wound, published in Braz J Otorhinolaryngol (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Braz J Otorhinolaryngol (2022)
Reported sample size
3
Source database
Europe PMC
PMID
34023243
PMCID
PMC9422660
DOI
10.1016/j.bjorl.2021.04.004
Citations
21

Abstract (original English)

Introduction Increased incidence of localized osteonecrosis in the jaw bones caused by bisphosphanate use and reduced quality of life of the patients led researchers to diagnose the disease in the early period and to investigate the effective treatment modality. Objective Treatment of medication-related osteonecrosis of the jaw patients is based on individual protocols from clinical experience, as there are no definitive treatment guidelines. In view of the lack of consensus on the effectiveness of medication-related osteonecrosis of the jaw treatments in the literature, the aim of this study was to evaluate the surgical technique described in the treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Methods Twenty-one patients affected by Stage 2-3 medication-related osteonecrosis of the jaw were treated with ultrasonic piezoelectric bone surgery for necrotic bone removing, leukocyte and platelet-rich fibrin concentrate obtained from the patient's peripheral blood and Nd:YAG laser for biostimulation. Success was assessed as the maintenance of full mucosal coverage without signs of residual infection at 1-month (T1), 3-months (T2), 6-months (T3) and 1-year (T4) after surgery. Logistic regressions were used to evaluate the association between the different independent variables and treatment outcomes. Results Two Stage 3 patients had delayed heali

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansTreatment OutcomeWound HealingQuality of LifeBisphosphonate-Associated Osteonecrosis of the Jaw

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research